Parker Institute's John Connolly provides an update on the latest in cancer immunotherapy at #JPM23.

Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.

Seagen's David Epstein talks about antibody-drug conjugates at #JPM23.

Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.

BTIG biotechnology analyst Justin Zelin gives his take on the news at #JPM23.

Moderna CEO Stéphane Bancel discusses his company's personalized cancer vaccine on Day Two of #JPM23 in San Francisco.

Centerview Partners' Eric Tokat talks about the M&A deals that have been announced at #JPM23.

Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.

Luke Timmerman fills us in on the latest at the Timmerman Report and his upcoming climb for cancer research of Mount Kilimanjaro at #JPM23.

Jorge Conde tells us about a16z's philosophy for investing in healthcare at #JPM23.

Flagship Pioneering’s Noubar Afeyan gives his take on the biotech sector for the year ahead at #JPM23.